Details for Patent: 6,432,452

« Back to Dashboard

Which drugs does patent 6,432,452 protect, and when does it expire?

Patent 6,432,452 protects PICATO and is included in one NDA. There has been one Paragraph IV challenge on Picato.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 6,432,452

Title:	Anti-cancer compounds
Abstract:	This invention relates to a compound or group of compounds present in an active principle derived from plants of the species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s):	Aylward; James Harrison (St. Lucia, AU)
Assignee:	Peplin Biotech Pty. Ltd. (Fortitude Valley, AU)
Application Number:	09/486,199
Patent Claim Types: see list of patent claims	Use; Process;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Patented / Exclusive Use
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012	RX	Yes	Yes	6,432,452	► Subscribe	TREATMENT OF ACTINIC KERATOSIS
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-002	Jan 23, 2012	RX	Yes	Yes	6,432,452	► Subscribe	TREATMENT OF ACTINIC KERATOSIS

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,432,452

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	PO 8640	Aug 19, 1997

PCT Information
PCT Filed	August 19, 1998	PCT Application Number:	PCT/AU98/00656
PCT Publication Date:	February 25, 1999	PCT Publication Number:	WO99/08994

Non-Orange Book Patents for Patent: 6,432,452

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,410,656	Anti-cancer compounds	► Subscribe
6,787,161	Anti-cancer compounds	► Subscribe
6,844,013	Methods of stimulating the immune system	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,432,452

Country	Document Number	Estimated Expiration
Australia	736230	► Subscribe
Australia	PO864097	► Subscribe
Brazil	9811327	► Subscribe
Canada	2301082	► Subscribe
China	1266421	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 6,432,452

« Back to Dashboard

Summary for Patent: 6,432,452

Glossary

Foreign Priority and PCT Information for Patent: 6,432,452

Non-Orange Book Patents for Patent: 6,432,452

International Patent Family for Patent: 6,432,452

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Get our Free Drug Patent Bulletin